文献速递乳腺US

联合治疗前B型乳腺超声BI-RADS®描述词与临床病理肿瘤特征的模型在预测新辅助化疗后残留病灶方面显示出前景

A model combining BI-RADS® descriptors from pre-treatment B-mode breast ultrasound with clinicopathological tumor features shows promise in the prediction of residual disease after neoadjuvant chemotherapy.
PubMed 文献 · Eur J Radiol · 2024-07-26

回顾性纳入2017年1月至2019年12月接受新辅助化疗的245例女性乳腺癌患者,由两名乳腺影像研究员独立评估基线B型超声图像并提取临床病理特征,在170例训练集中用逻辑回归建立残留病灶预测模型,83例验证集评估。100例(40.8%)达到病理完全缓解,模型预测残留肿瘤的ROC曲线下面积训练集为0.873、验证集为0.720。

要点

  • 肿瘤大小、微小分叶边缘、毛刺状边缘、钙化、水肿、HER2阳性亚型及三阴性亚型为新辅助化疗后残留病灶的独立预测因子。
  • 联合上述BI-RADS®描述词与临床病理特征的模型预测残留肿瘤的AUC训练集0.873、验证集0.720。
  • 参考标准为术后组织学,判定乳腺或腋窝淋巴结有无残留浸润性肿瘤以定义病理完全缓解(pCR)或非pCR。

核心结论

  • 联合治疗前B型乳腺超声标准BI-RADS®描述词与临床病理肿瘤特征的简单模型可预测新辅助化疗后残留病灶的存在。

研究设计与样本

  • 回顾性研究,纳入245例接受新辅助化疗的女性乳腺癌患者,数据分为170例训练集与83例验证集,两名乳腺影像研究员独立评估基线B型超声代表性肿瘤图像,采用逻辑回归在训练集筛选独立预测因子并建模,以术后组织学(乳腺或腋窝淋巴结有无残留浸润性肿瘤)为参考标准。

诊断标准与关键数值

  • 模型预测新辅助化疗后残留肿瘤的ROC曲线下面积:训练集0.873,验证集0.720。
  • 独立预测残留病灶的参数:肿瘤大小、微小分叶边缘、毛刺状边缘、钙化存在、水肿存在、HER2阳性分子亚型、三阴性分子亚型。

临床应用与阅片要点

  • 治疗前B型超声评估肿瘤大小时,应关注边缘特征(微小分叶、毛刺状)、钙化及水肿,这些BI-RADS®描述词与临床病理特征联合可用于预测新辅助化疗后残留病灶。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To create a simple model using standard BI-RADS® descriptors from pre-treatment B-mode ultrasound (US) combined with clinicopathological tumor features, and to assess the potential of the model to predict the presence of residual tumor after neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients.

METHOD: 245 female BC patients receiving NAC between January 2017 and December 2019 were included in this retrospective study. Two breast imaging fellows independently evaluated representative B-mode tumor images from baseline US. Additional clinicopathological tumor features were retrieved. The dataset was split into 170 training and 83 validation cases. Logistic regression was used in the training set to identify independent predictors of residual disease post NAC and to create a model, whose performance was evaluated by ROC curve analysis in the validation set. The reference standard was postoperative histology to determine the absence (pathological complete response, pCR) or presence (non-pCR) of residual invasive tumor in the breast or axillary lymph nodes.

RESULTS: 100 patients (40.8%) achieved pCR. Logistic regression demonstrated that tumor size, microlobulated margin, spiculated margin, the presence of calcifications, the presence of edema, HER2-positive molecular subtype, and triple-negative molecular subtype were independent predictors of residual disease. A model using these parameters demonstrated an area under the ROC curve of 0.873 in the training and 0.720 in the validation set for the prediction of residual tumor post NAC.

CONCLUSIONS: A simple model combining standard BI-RADS® descriptors from pre-treatment B-mode breast US with clinicopathological tumor features predicts the presence of residual disease after NAC.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Kapetas P, Aggarwal R, Altuwayjiri B, et al. A model combining BI-RADS® descriptors from pre-treatment B-mode breast ultrasound with clinicopathological tumor features shows promise in the prediction of residual disease after neoadjuvant chemotherapy. Eur J Radiol. 2024. PMID: 39094464. doi:10.1016/j.ejrad.2024.111649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。